EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases

Reddemma Sandireddy, Suganya Sakthivel, Priyanka Gupta, Jatin Behari, Madhulika Tripathi, Brijesh Kumar Singh

Frontiers in Cell and Developmental Biology · 16.07.2024 · 12

DOI: 10.3389/fcell.2024.1433857 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 16.07.2024. Verfasst von Reddemma Sandireddy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular and Metabolic Disorders Research Program, Duke-NUS Medical School, Singapore, Singapore. Die Arbeit wurde bisher 237-mal zitiert (Crossref) und nennt 224 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is the most common liver disorder worldwide, with an estimated global prevalence of more than 31%. Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), is a progressive form of MASLD characterized by hepatic steatosis, inflammation, and fibrosis. This review aims to provide a comprehensive analysis of the extrahepatic manifestations of MASH, focusing on chronic diseases related to the cardiovascular, muscular, and renal systems. A systematic review of published studies and literature was conducted to summarize the findings related to the systemic impacts of MASLD and MASH. The review focused on the association of MASLD and MASH with metabolic comorbidities, cardiovascular mortality, sarcopenia, and chronic kidney disease. Mechanistic insights into the concept of lipotoxic inflammatory “spill over” from the MASH-affected liver were also explored. MASLD and MASH are highly associated (50%–80%) with other metabolic comorbidities such as impaired insulin response, type 2 diabetes, dyslipidemia, hypertriglyceridemia, and hypertension. Furthermore, more than 90% of obese patients with type 2 diabetes have MASH. Data suggest that in middle-aged individuals (especially those aged 45–54), MASLD is an independent risk factor for cardiovascular mortality, sarcopenia, and chronic kidney disease. The concept of lipotoxic inflammatory “spill over” from the MASH-affected liver plays a crucial role in mediating the systemic pathological effects observed. Understanding the multifaceted impact of MASH on the heart, muscle, and kidney is crucial for early detection and risk stratification. This knowledge is also timely for implementing comprehensive disease management strategies addressing multi-organ involvement in MASH pathogenesis.

Schlagwörter

Stichwörter der Autor:innen

Adipose tissue (AT)cardiovascular diseases (CVDs)chronic kidney diseases (CKDs)heartmetabolic dysfunction-associated steatohepatitis (MASH)/non-alcoholic steatohep…metabolic dysfunction-associated steatotic liver disease (MASLD)/non-alcoholic…musclesarcopenia

Autor:innen und Institutionen

  • Cardiovascular and Metabolic Disorders Research Program, Duke-NUS Medical School, Singapore, Singapore.

Förderung

  • National Medical Research Council

Zitieren

APA

Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., & Singh, B. K. (2024). Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Frontiers in Cell and Developmental Biology, 12. https://doi.org/10.3389/fcell.2024.1433857

Vancouver

Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, Singh BK. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Frontiers in Cell and Developmental Biology. 2024;12. doi:10.3389/fcell.2024.1433857

BibTeX
@article{Sandireddy2024,
  author = {Sandireddy, Reddemma and Sakthivel, Suganya and Gupta, Priyanka and Behari, Jatin and Tripathi, Madhulika and Singh, Brijesh Kumar},
  title = {Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2024},
  volume = {12},
  doi = {10.3389/fcell.2024.1433857}
}
Kostenlos starten →